Free Trial
→ AI Meltdown Imminent: Dump These Stocks Now! (From Paradigm Press) (Ad) Buy ANGO Stock  Free ANGO Stock Alerts

AngioDynamics (ANGO) Financials

AngioDynamics logo
$10.25 +0.54 (+5.56%)
As of 02:53 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for AngioDynamics

Annual Income Statements for AngioDynamics

This table shows AngioDynamics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 5/31/2024 5/31/2023 5/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -184 -52 -27
Consolidated Net Income / (Loss)		 -184 -52 -27
Net Income / (Loss) Continuing Operations		 -184 -52 -27
Total Pre-Tax Income 		-192 -54 -30
Total Operating Income		 -192 -51 -28
Total Gross Profit		 155 174 166
Total Revenue		 304 339 316
Operating Revenue		 304 339 316
Total Cost of Revenue		 149 165 150
Operating Cost of Revenue		 149 165 150
Total Operating Expenses		 347 225 194
Selling, General & Admin Expense		 41 40 38
Marketing Expense		 103 104 95
Research & Development Expense		 32 30 31
Amortization Expense		 13 19 19
Other Operating Expenses / (Income)		 0.43 2.32 1.21
Impairment Charge		 159 15 0.00
Restructuring Charge		 53 16 9.04
Other Special Charges / (Income)		 -54 0.00 0.00
Total Other Income / (Expense), net		 0.80 -3.26 -1.48
Interest Expense		 -1.61 2.70 0.69
Other Income / (Expense), net		 -0.82 -0.55 -0.79
Income Tax Expense		 -7.29 -2.00 -3.40
Basic Earnings per Share		 ($4.59) ($1.33) ($0.68)
Weighted Average Basic Shares Outstanding		 40.18M 39.48M 39.01M
Diluted Earnings per Share		 ($4.59) ($1.33) ($0.68)
Weighted Average Diluted Shares Outstanding		 40.18M 39.48M 39.01M
Weighted Average Basic & Diluted Shares Outstanding		 40.28M 39.67M 38.97M

Quarterly Income Statements for AngioDynamics

This table shows AngioDynamics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 2/28/2025 11/30/2024 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023 11/30/2022 8/31/2022
Net Income / (Loss) Attributable to Common Shareholders		 -4.41 -11 -13 -13 -188 -29 46 -21 -9.49 -8.49 -13
Consolidated Net Income / (Loss)		 -4.41 -11 -13 -13 -188 -29 46 -21 -9.49 -8.49 -13
Net Income / (Loss) Continuing Operations		 -4.41 -11 -13 -13 -188 -29 46 -21 -9.49 -8.49 -13
Total Pre-Tax Income 		-4.41 -11 -13 -14 -200 -13 35 -22 -9.66 -9.05 -14
Total Operating Income		 -9.97 -11 -13 -14 -200 -13 35 -21 -8.93 -8.12 -13
Total Gross Profit		 39 40 37 39 36 40 40 46 41 45 42
Total Revenue		 72 73 67 71 75 79 79 91 81 85 82
Operating Revenue		 72 73 67 71 75 79 79 91 81 85 82
Total Cost of Revenue		 33 33 31 32 39 39 39 45 40 40 39
Operating Cost of Revenue		 33 33 31 32 39 39 39 45 40 40 39
Total Operating Expenses		 49 51 50 53 236 53 5.03 67 49 53 56
Selling, General & Admin Expense		 10 10 11 10 11 9.29 11 10 8.84 11 10
Marketing Expense		 26 26 26 25 25 25 27 26 25 26 27
Research & Development Expense		 6.91 6.43 6.29 6.72 8.19 8.66 7.94 7.86 6.85 6.84 8.33
Amortization Expense		 2.60 2.56 2.57 2.57 3.29 3.56 3.63 4.41 4.74 4.81 4.84
Other Operating Expenses / (Income)		 0.04 0.16 0.08 0.23 0.11 0.22 -0.13 0.24 0.23 1.65 0.21
Impairment Charge		 0.00 - - - 159 - - - 0.00 - -
Restructuring Charge		 3.29 5.87 4.31 8.42 35 6.19 3.21 3.62 3.37 3.06 5.58
Other Special Charges / (Income)		 0.00 0.00 0.00 - -6.66 0.00 -48 - 0.00 0.00 0.00
Total Other Income / (Expense), net		 5.57 0.25 0.43 0.31 0.16 0.50 -0.17 -1.03 -0.74 -0.94 -0.56
Interest & Investment Income		 0.14 0.23 0.61 - 0.39 0.53 0.12 - - - -
Other Income / (Expense), net		 5.43 0.01 -0.17 -0.26 -0.24 -0.03 -0.29 -0.13 0.00 -0.25 -0.18
Income Tax Expense		 -0.00 -0.11 0.13 -0.69 -12 16 -11 -0.40 -0.18 -0.57 -0.85
Basic Earnings per Share		 ($0.11) ($0.26) ($0.31) ($0.35) ($4.67) ($0.72) $1.15 ($0.55) ($0.24) ($0.21) ($0.33)
Weighted Average Basic Shares Outstanding		 40.85M 40.92M 40.65M 40.18M 40.23M 40.22M 39.84M 39.48M 39.51M 39.49M 39.30M
Diluted Earnings per Share		 ($0.11) ($0.26) ($0.31) ($0.35) ($4.67) ($0.72) $1.15 ($0.55) ($0.24) ($0.21) ($0.33)
Weighted Average Diluted Shares Outstanding		 40.85M 40.92M 40.65M 40.18M 40.23M 40.22M 39.97M 39.48M 39.51M 39.49M 39.30M
Weighted Average Basic & Diluted Shares Outstanding		 40.61M 40.47M 40.63M 40.28M 40.05M 39.86M 39.85M 39.67M 39.24M 39.13M 39.11M

Annual Cash Flow Statements for AngioDynamics

This table details how cash moves in and out of AngioDynamics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 5/31/2024 5/31/2023 5/31/2022
Net Change in Cash & Equivalents		 31 16 -19
Net Cash From Operating Activities		 -28 0.08 -7.19
Net Cash From Continuing Operating Activities		 -28 0.08 -7.19
Net Income / (Loss) Continuing Operations		 -184 -52 -27
Consolidated Net Income / (Loss)		 -184 -52 -27
Depreciation Expense		 28 31 29
Non-Cash Adjustments To Reconcile Net Income		 122 29 14
Changes in Operating Assets and Liabilities, net		 6.89 -7.02 -24
Net Cash From Investing Activities		 124 -9.75 -19
Net Cash From Continuing Investing Activities		 124 -9.75 -19
Purchase of Property, Plant & Equipment		 -2.52 -3.81 -4.30
Acquisitions		 -3.25 -0.54 -3.60
Divestitures		 135 0.00 0.00
Other Investing Activities, net		 -5.02 -5.39 -11
Net Cash From Financing Activities		 -64 25 7.68
Net Cash From Continuing Financing Activities		 -64 25 7.68
Repayment of Debt		 -50 -46 0.00
Issuance of Debt		 0.00 70 5.00
Other Financing Activities, net		 -14 1.17 2.68
Effect of Exchange Rate Changes		 0.13 0.04 -0.52
Cash Interest Paid		 0.00 2.58 0.56
Cash Income Taxes Paid		 0.46 0.34 0.33

Quarterly Cash Flow Statements for AngioDynamics

This table details how cash moves in and out of AngioDynamics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 2/28/2025 11/30/2024 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023 11/30/2022 8/31/2022
Net Change in Cash & Equivalents		 -9.33 -0.92 -21 -2.40 18 3.31 13 15 0.25 5.29 -4.26
Net Cash From Operating Activities		 -13 2.47 -18 5.00 -13 5.27 -26 16 1.37 7.50 -25
Net Cash From Continuing Operating Activities		 -13 2.47 -18 5.00 -13 5.27 -26 16 1.37 7.50 -25
Net Income / (Loss) Continuing Operations		 -4.41 -11 -13 -13 -188 -29 46 -21 -9.49 -8.49 -13
Consolidated Net Income / (Loss)		 -4.41 -11 -13 -13 -188 -29 46 -21 -9.49 -8.49 -13
Depreciation Expense		 6.32 6.86 6.79 6.82 7.52 6.69 6.69 7.56 7.84 7.82 7.66
Non-Cash Adjustments To Reconcile Net Income		 3.15 3.34 4.19 2.30 161 3.25 -45 16 2.62 6.02 3.89
Changes in Operating Assets and Liabilities, net		 -18 3.01 -16 9.33 6.72 24 -34 14 0.40 2.14 -23
Net Cash From Investing Activities		 -3.19 -1.96 -2.41 -2.34 29 -1.79 98 -1.53 -2.15 -2.50 -3.58
Net Cash From Continuing Investing Activities		 -3.19 -1.96 -2.41 -2.34 29 -1.79 98 -1.53 -2.15 -2.50 -3.58
Purchase of Property, Plant & Equipment		 -3.19 -1.96 -2.41 2.68 -1.85 -1.79 -1.56 3.87 -2.15 -2.50 -3.04
Net Cash From Financing Activities		 7.15 -1.12 -0.51 -5.00 0.69 -0.35 -60 - 0.94 0.10 24
Net Cash From Continuing Financing Activities		 7.15 -1.12 -0.51 -5.00 0.69 -0.35 -60 - 0.94 0.10 24
Issuance of Common Equity		 0.90 -0.01 0.04 - 0.69 -0.35 0.41 - 0.94 0.15 0.08
Other Financing Activities, net		 -0.06 - 0.00 -4.25 - - -10 1.17 - - 0.00
Effect of Exchange Rate Changes		 -0.13 -0.31 0.12 -0.06 -0.02 0.19 0.01 0.08 0.09 0.19 -0.32

Annual Balance Sheets for AngioDynamics

This table presents AngioDynamics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 5/31/2024 5/31/2023 5/31/2022
Total Assets		 318 533 553
Total Current Assets		 193 164 143
Cash & Equivalents		 76 45 29
Accounts Receivable		 44 53 52
Inventories, net		 61 55 51
Prepaid Expenses		 13 4.62 11
Other Current Assets		 0.00 - -
Plant, Property, & Equipment, net		 36 44 45
Total Noncurrent Assets		 89 325 364
Intangible Assets		 77 111 152
Other Noncurrent Operating Assets		 11 11 11
Total Liabilities & Shareholders' Equity		 318 533 553
Total Liabilities		 112 154 128
Total Current Liabilities		 91 84 74
Short-Term Debt		 4.73 15 8.78
Accounts Payable		 38 40 28
Accrued Expenses		 41 27 35
Other Current Liabilities		 7.58 2.00 2.65
Total Noncurrent Liabilities		 21 71 54
Noncurrent Deferred & Payable Income Tax Liabilities		 4.85 13 16
Other Noncurrent Operating Liabilities		 16 7.89 13
Commitments & Contingencies		 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 206 378 424
Total Preferred & Common Equity		 206 378 424
Preferred Stock		 0.00 0.00 0.00
Total Common Equity		 206 378 424
Common Stock		 611 600 587
Retained Earnings		 -395 -211 -158
Treasury Stock		 -5.71 -5.71 -5.71
Accumulated Other Comprehensive Income / (Loss)		 -4.37 -4.72 1.36

Quarterly Balance Sheets for AngioDynamics

This table presents AngioDynamics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2025 Q2 2025 Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023
Period end date 2/28/2025 11/30/2024 8/31/2024 2/29/2024 11/30/2023 8/31/2023 2/28/2023 11/30/2022 8/31/2022
Total Assets		 285 292 294 325 500 494 543 558 558
Total Current Assets		 172 175 173 197 185 175 153 159 151
Cash & Equivalents		 45 54 55 78 61 58 30 30 25
Accounts Receivable		 43 43 40 49 52 50 51 53 54
Inventories, net		 63 66 65 58 64 60 64 63 58
Prepaid Expenses		 15 12 13 11 8.72 8.16 8.04 13 16
Other Current Assets		 5.50 - - - - - - - -
Plant, Property, & Equipment, net		 33 33 34 37 43 43 46 46 46
Total Noncurrent Assets		 81 83 87 91 272 275 345 353 360
Intangible Assets		 71 73 76 82 104 107 134 142 148
Other Noncurrent Operating Assets		 9.68 10 11 9.33 8.48 9.43 11 11 11
Total Liabilities & Shareholders' Equity		 285 292 294 325 500 494 543 558 558
Total Liabilities		 100 105 97 106 98 66 145 150 144
Total Current Liabilities		 78 89 77 86 78 57 70 74 66
Short-Term Debt		 5.00 4.96 4.80 9.50 9.39 4.73 9.88 9.76 8.89
Accounts Payable		 30 35 31 35 38 25 36 35 29
Accrued Expenses		 37 40 34 31 29 26 22 27 26
Other Current Liabilities		 5.76 8.97 6.52 10 1.76 1.84 2.38 2.59 2.68
Total Noncurrent Liabilities		 22 16 20 20 20 8.69 76 77 77
Noncurrent Deferred & Payable Income Tax Liabilities		 4.20 4.33 4.63 5.92 18 1.28 13 14 15
Other Noncurrent Operating Liabilities		 17 12 16 14 2.60 7.41 12 13 12
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 186 187 197 219 401 428 398 408 414
Total Preferred & Common Equity		 186 187 197 219 401 428 398 408 414
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 186 187 197 219 401 428 398 408 414
Common Stock		 620 617 614 609 606 604 597 594 590
Retained Earnings		 -423 -419 -408 -382 -194 -165 -189 -180 -171
Treasury Stock		 -7.38 -7.38 -6.27 -5.71 -5.71 -5.71 -5.71 -5.71 -5.71
Accumulated Other Comprehensive Income / (Loss)		 -3.53 -3.75 -3.27 -2.81 -4.71 -5.65 -3.85 -0.29 0.81

Annual Metrics And Ratios for AngioDynamics

This table displays calculated financial ratios and metrics derived from AngioDynamics' official financial filings.

Metric 2024 2023 2022
Period end date 5/31/2024 5/31/2023 5/31/2022
Growth Metrics		 - - -
Revenue Growth		 -10.28% 7.13% 8.66%
EBITDA Growth		 -693.50% -23,806.82% 100.95%
EBIT Growth		 -273.54% -76.81% 16.85%
NOPAT Growth		 -275.99% -79.77% 19.31%
Net Income Growth		 -251.53% -97.54% 15.85%
EPS Growth		 -245.11% -95.59% 17.07%
Operating Cash Flow Growth		 -36,200.00% 101.08% -129.86%
Free Cash Flow Firm Growth		 75.96% 218.62% -9.68%
Invested Capital Growth		 -61.47% -18.86% 4.41%
Revenue Q/Q Growth		 -6.20% 1.22% 3.32%
EBITDA Q/Q Growth		 3.22% -229.89% 100.57%
EBIT Q/Q Growth		 3.14% -38.67% 32.98%
NOPAT Q/Q Growth		 3.21% -39.30% 34.79%
Net Income Q/Q Growth		 4.17% -40.82% 33.21%
EPS Q/Q Growth		 4.18% -41.49% 33.98%
Operating Cash Flow Q/Q Growth		 -63.66% 101.07% -102.36%
Free Cash Flow Firm Q/Q Growth		 -42.53% 303.99% -23.25%
Invested Capital Q/Q Growth		 -10.34% -18.44% -0.31%
Profitability Metrics		 - - -
Gross Margin		 50.90% 51.44% 52.41%
EBITDA Margin		 -54.47% -6.16% 0.03%
Operating Margin		 -63.32% -15.11% -9.00%
EBIT Margin		 -63.59% -15.27% -9.25%
Profit (Net Income) Margin		 -60.66% -15.48% -8.40%
Tax Burden Percent		 96.20% 96.34% 88.64%
Interest Burden Percent		 99.16% 105.22% 102.35%
Effective Tax Rate		 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -55.81% -9.21% -4.74%
ROIC Less NNEP Spread (ROIC-NNEP)		 42.32% 124.30% 52.30%
Return on Net Nonoperating Assets (RNNOA)		 -7.33% -3.85% -1.40%
Return on Equity (ROE)		 -63.15% -13.07% -6.15%
Cash Return on Invested Capital (CROIC)		 32.93% 11.61% -9.06%
Operating Return on Assets (OROA)		 -45.45% -9.53% -5.25%
Return on Assets (ROA)		 -43.36% -9.66% -4.77%
Return on Common Equity (ROCE)		 -63.15% -13.07% -6.15%
Return on Equity Simple (ROE_SIMPLE)		 -89.67% -13.86% -6.25%
Net Operating Profit after Tax (NOPAT)		 -135 -36 -20
NOPAT Margin		 -44.32% -10.58% -6.30%
Net Nonoperating Expense Percent (NNEP)		 -98.13% -133.51% -57.04%
Cost of Revenue to Revenue		 49.10% 48.56% 47.59%
SG&A Expenses to Revenue		 13.54% 11.81% 12.16%
R&D to Revenue		 10.37% 8.82% 9.72%
Operating Expenses to Revenue		 114.22% 66.55% 61.41%
Earnings before Interest and Taxes (EBIT)		 -193 -52 -29
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -166 -21 0.09
Valuation Ratios		 - - -
Price to Book Value (P/BV)		 1.23 0.98 1.79
Price to Tangible Book Value (P/TBV)		 1.97 3.44 10.71
Price to Revenue (P/Rev)		 0.83 1.10 2.41
Price to Earnings (P/E)		 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.35 1.12 1.78
Enterprise Value to Revenue (EV/Rev)		 0.60 1.15 2.42
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 8,706.95
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 5,014.56 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 2.28 8.66 0.00
Leverage & Solvency		 - - -
Debt to Equity		 0.02 0.17 0.08
Long-Term Debt to Equity		 0.00 0.13 0.06
Financial Leverage		 -0.17 -0.03 -0.03
Leverage Ratio		 1.46 1.35 1.29
Compound Leverage Factor		 1.44 1.42 1.32
Debt to Total Capital		 2.25% 14.58% 7.37%
Short-Term Debt to Total Capital		 2.25% 3.33% 1.92%
Long-Term Debt to Total Capital		 0.00% 11.25% 5.46%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.75% 85.42% 92.63%
Debt to EBITDA		 -0.03 -3.10 383.90
Net Debt to EBITDA		 0.43 -0.96 56.34
Long-Term Debt to EBITDA		 0.00 -2.39 284.09
Debt to NOPAT		 -0.04 -1.80 -1.70
Net Debt to NOPAT		 0.53 -0.56 -0.25
Long-Term Debt to NOPAT		 0.00 -1.39 -1.25
Altman Z-Score		 -1.05 1.38 3.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00%
Liquidity Ratios		 - - -
Current Ratio		 2.12 1.95 1.93
Quick Ratio		 1.31 1.16 1.09
Cash Flow Metrics		 - - -
Free Cash Flow to Firm (FCFF)		 79 45 -38
Operating Cash Flow to CapEx		 -1,118.27% 2.05% -167.42%
Free Cash Flow to Firm to Interest Expense		 0.00 16.72 -55.35
Operating Cash Flow to Interest Expense		 0.00 0.03 -10.46
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -1.38 -16.70
Efficiency Ratios		 - - -
Asset Turnover		 0.71 0.62 0.57
Accounts Receivable Turnover		 6.30 6.44 7.21
Inventory Turnover		 2.57 3.08 3.01
Fixed Asset Turnover		 7.59 7.58 7.71
Accounts Payable Turnover		 3.82 4.80 6.31
Days Sales Outstanding (DSO)		 57.91 56.64 50.62
Days Inventory Outstanding (DIO)		 141.80 118.39 121.28
Days Payable Outstanding (DPO)		 95.64 75.98 57.82
Cash Conversion Cycle (CCC)		 104.07 99.04 114.08
Capital & Investment Metrics		 - - -
Invested Capital		 134 348 429
Invested Capital Turnover		 1.26 0.87 0.75
Increase / (Decrease) in Invested Capital		 -214 -81 18
Enterprise Value (EV)		 181 391 766
Market Capitalization		 253 371 761
Book Value per Share		 $5.13 $9.64 $10.95
Tangible Book Value per Share		 $3.20 $2.75 $1.83
Total Capital		 210 443 458
Total Debt		 4.73 65 34
Total Long-Term Debt		 0.00 50 25
Net Debt		 -71 20 4.96
Capital Expenditures (CapEx)		 2.52 3.81 4.30
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 31 50 49
Debt-free Net Working Capital (DFNWC)		 107 94 78
Net Working Capital (NWC)		 102 80 69
Net Nonoperating Expense (NNE)		 50 17 6.62
Net Nonoperating Obligations (NNO)		 -71 -30 4.96
Total Depreciation and Amortization (D&A)		 28 31 29
Debt-free, Cash-free Net Working Capital to Revenue		 10.12% 14.72% 15.49%
Debt-free Net Working Capital to Revenue		 35.15% 27.89% 24.60%
Net Working Capital to Revenue		 33.59% 23.53% 21.83%
Earnings Adjustments		 - - -
Adjusted Basic Earnings per Share		 ($4.59) ($1.33) ($0.68)
Adjusted Weighted Average Basic Shares Outstanding		 40.18M 39.48M 39.01M
Adjusted Diluted Earnings per Share		 ($4.59) ($1.33) ($0.68)
Adjusted Weighted Average Diluted Shares Outstanding		 40.18M 39.48M 39.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.28M 39.67M 38.97M
Normalized Net Operating Profit after Tax (NOPAT)		 -24 -15 -14
Normalized NOPAT Margin		 -7.89% -4.34% -4.30%
Pre Tax Income Margin		 -63.06% -16.07% -9.47%
Debt Service Ratios		 - - -
EBIT to Interest Expense		 0.00 -19.15 -42.53
NOPAT to Interest Expense		 0.00 -13.26 -28.97
EBIT Less CapEx to Interest Expense		 0.00 -20.56 -48.78
NOPAT Less CapEx to Interest Expense		 0.00 -14.67 -35.21
Payout Ratios		 - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for AngioDynamics

This table displays calculated financial ratios and metrics derived from AngioDynamics' official financial filings.

Metric Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023
Period end date 2/28/2025 11/30/2024 8/31/2024 5/31/2024 2/29/2024 11/30/2023 8/31/2023 5/31/2023 2/28/2023 11/30/2022 8/31/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -4.23% -7.88% -14.22% -22.06% -6.85% -7.44% -3.51% 4.69% 9.11% 9.13% 5.93%
EBITDA Growth		 100.92% 34.76% -115.66% 41.14% -17,570.83% -1,077.96% 812.35% -1,285.41% -159.82% 61.06% -299.73%
EBIT Growth		 97.73% 15.74% -138.20% 29.84% -2,141.64% -57.19% 357.81% -220.75% -59.89% 3.71% -59.44%
NOPAT Growth		 95.01% 15.44% -119.89% 30.66% -2,138.98% -61.68% 595.20% -225.73% -68.61% 6.50% -64.21%
Net Income Growth		 97.65% 63.03% -127.89% 37.35% -1,879.29% -242.31% 452.85% -242.60% -91.31% -1.62% -86.52%
EPS Growth		 97.64% 63.89% -126.96% 36.36% -1,845.83% -242.86% 448.48% -243.75% -84.62% 0.00% -83.33%
Operating Cash Flow Growth		 -5.05% -53.04% 29.52% -68.65% -1,014.31% -29.78% -4.66% 86.38% 115.58% 286.35% -177.91%
Free Cash Flow Firm Growth		 -102.43% 159.42% 83.86% 207.28% 5,241.05% 488.72% 472.90% 393.49% 33.80% -382.74% -300.29%
Invested Capital Growth		 -2.43% -60.64% -60.96% -61.47% -64.95% -20.09% -16.34% -18.86% -0.83% 3.45% 5.33%
Revenue Q/Q Growth		 -1.15% 7.93% -4.92% -5.59% -4.92% 0.50% -13.61% 12.84% -5.52% 4.77% -6.28%
EBITDA Q/Q Growth		 142.07% 34.95% 17.81% 95.90% -2,878.38% -115.61% 409.02% -1,130.00% -98.54% 90.56% -614.24%
EBIT Q/Q Growth		 59.00% 16.49% 9.77% 92.65% -1,421.70% -137.86% 265.72% -134.81% -6.70% 37.91% -106.18%
NOPAT Q/Q Growth		 10.10% 15.30% 9.35% 92.77% -1,423.60% -119.92% 416.10% -133.39% -10.02% 38.99% -107.93%
Net Income Q/Q Growth		 58.96% 16.10% 4.84% 92.84% -546.30% -163.31% 313.74% -126.33% -11.77% 34.74% -107.53%
EPS Q/Q Growth		 57.69% 16.13% 11.43% 92.51% -548.61% -162.61% 309.09% -129.17% -14.29% 36.36% -106.25%
Operating Cash Flow Q/Q Growth		 -632.11% 113.55% -464.99% 139.93% -337.87% 120.33% -262.34% 1,064.53% -81.73% 130.31% -389.08%
Free Cash Flow Firm Q/Q Growth		 -101.64% -6.88% 7.51% 48.36% 74.66% -34.00% 79.67% 2,582.18% 86.79% 36.69% -41.41%
Invested Capital Q/Q Growth		 6.15% -5.97% 9.03% -10.34% -57.18% -6.73% 7.60% -18.44% -2.38% -2.35% 4.36%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 53.97% 54.78% 54.41% 54.26% 47.70% 50.92% 50.92% 50.90% 50.18% 52.77% 51.88%
EBITDA Margin		 2.47% -5.79% -9.61% -11.12% -256.19% -8.18% 52.66% -14.72% -1.35% -0.64% -7.13%
Operating Margin		 -13.85% -15.23% -19.41% -20.36% -265.88% -16.59% 44.52% -22.88% -11.06% -9.50% -16.31%
EBIT Margin		 -6.31% -15.21% -19.66% -20.72% -266.20% -16.63% 44.16% -23.02% -11.06% -9.79% -16.53%
Profit (Net Income) Margin		 -6.12% -14.74% -18.96% -18.95% -249.71% -36.74% 58.32% -23.57% -11.75% -9.93% -15.95%
Tax Burden Percent		 99.95% 98.99% 101.05% 95.11% 93.99% 230.21% 131.62% 98.18% 98.15% 93.76% 93.84%
Interest Burden Percent		 97.03% 97.89% 95.43% 96.15% 99.80% 95.94% 100.34% 104.30% 108.24% 108.18% 102.83%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -31.62% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -18.57% -12.53% -15.26% -17.94% -209.03% -9.72% 47.83% -13.95% -6.04% -5.07% -8.39%
ROIC Less NNEP Spread (ROIC-NNEP)		 -23.31% -6.63% -8.21% -11.35% 33.79% 172.43% 50.20% 41.34% -27.13% -32.56% -39.61%
Return on Net Nonoperating Assets (RNNOA)		 6.26% 1.13% 1.36% 1.97% -2.16% -4.65% -1.12% -1.28% -1.01% -0.79% -1.10%
Return on Equity (ROE)		 -12.31% -11.40% -13.90% -15.98% -211.19% -14.37% 46.71% -15.23% -7.05% -5.86% -9.49%
Cash Return on Invested Capital (CROIC)		 -20.55% 18.51% 23.08% 32.93% 47.94% 20.94% 17.31% 11.61% -5.16% -8.77% -10.59%
Operating Return on Assets (OROA)		 -5.86% -11.02% -14.62% -14.81% -198.81% -10.36% 28.21% -14.37% -6.82% -5.78% -9.52%
Return on Assets (ROA)		 -5.68% -10.68% -14.10% -13.54% -186.49% -22.89% 37.25% -14.71% -7.24% -5.86% -9.19%
Return on Common Equity (ROCE)		 -12.31% -11.40% -13.90% -15.98% -211.19% -14.37% 46.71% -15.23% -7.05% -5.86% -9.49%
Return on Equity Simple (ROE_SIMPLE)		 -22.27% -120.32% -123.63% 0.00% -87.96% -3.52% 1.51% 0.00% -9.37% -8.02% -7.87%
Net Operating Profit after Tax (NOPAT)		 -6.98 -7.77 -9.17 -10 -140 -9.18 46 -15 -6.25 -5.68 -9.31
NOPAT Margin		 -9.70% -10.66% -13.58% -14.25% -186.12% -11.61% 58.60% -16.02% -7.74% -6.65% -11.42%
Net Nonoperating Expense Percent (NNEP)		 4.74% -5.91% -7.04% -6.59% -242.82% -182.16% -2.38% -55.29% 21.09% 27.49% 31.23%
Return On Investment Capital (ROIC_SIMPLE)		 -3.66% -4.05% - - -61.32% -2.24% - - - - -
Cost of Revenue to Revenue		 46.03% 45.22% 45.59% 45.74% 52.30% 49.08% 49.08% 49.10% 49.82% 47.23% 48.12%
SG&A Expenses to Revenue		 14.57% 14.26% 16.26% 14.71% 14.07% 11.75% 13.80% 11.23% 10.95% 12.68% 12.39%
R&D to Revenue		 9.60% 8.83% 9.31% 9.47% 10.89% 10.95% 10.09% 8.63% 8.49% 8.00% 10.22%
Operating Expenses to Revenue		 67.82% 70.01% 73.82% 74.62% 313.58% 67.51% 6.39% 73.78% 61.24% 62.27% 68.20%
Earnings before Interest and Taxes (EBIT)		 -4.54 -11 -13 -15 -200 -13 35 -21 -8.93 -8.37 -13
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 1.78 -4.22 -6.49 -7.89 -193 -6.47 41 -13 -1.09 -0.55 -5.82
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.02 1.51 1.53 1.23 1.00 0.65 0.74 0.98 1.22 1.24 2.08
Price to Tangible Book Value (P/TBV)		 3.27 2.48 2.49 1.97 1.60 1.88 1.97 3.44 7.61 7.76 13.27
Price to Revenue (P/Rev)		 1.33 0.98 1.03 0.83 0.68 0.79 0.95 1.10 1.45 1.54 2.69
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 49.42 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.02% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.30 1.69 1.71 1.35 1.00 0.60 0.71 1.12 1.20 1.23 2.00
Enterprise Value to Revenue (EV/Rev)		 1.19 0.81 0.85 0.60 0.46 0.63 0.79 1.15 1.54 1.63 2.80
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 10.20 10.07 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 5,014.56 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 5.15 4.16 2.28 1.08 2.53 3.73 8.66 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.03 0.03 0.02 0.02 0.04 0.02 0.01 0.17 0.15 0.15 0.14
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.13 0.13 0.12 0.12
Financial Leverage		 -0.27 -0.17 -0.17 -0.17 -0.06 -0.03 -0.02 -0.03 0.04 0.02 0.03
Leverage Ratio		 1.51 1.35 1.26 1.46 1.41 1.31 1.25 1.35 1.31 1.32 1.31
Compound Leverage Factor		 1.46 1.32 1.20 1.40 1.41 1.25 1.25 1.41 1.42 1.43 1.35
Debt to Total Capital		 2.62% 2.59% 2.39% 2.25% 4.16% 2.29% 1.09% 14.58% 13.05% 12.74% 12.42%
Short-Term Debt to Total Capital		 2.62% 2.59% 2.39% 2.25% 4.16% 2.29% 1.09% 3.33% 2.16% 2.09% 1.88%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11.25% 10.89% 10.65% 10.53%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 97.38% 97.41% 97.61% 97.75% 95.84% 97.71% 98.91% 85.42% 86.95% 87.26% 87.58%
Debt to EBITDA		 -0.30 -0.02 -0.02 -0.03 -0.06 0.46 0.18 -3.10 -9.44 -17.45 -13.74
Net Debt to EBITDA		 2.36 0.23 0.24 0.43 0.40 -2.52 -2.00 -0.96 -4.68 -8.70 -7.99
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2.39 -7.88 -14.59 -11.65
Debt to NOPAT		 -0.15 -0.03 -0.03 -0.04 -0.07 -1.71 -2.37 -1.80 -2.32 -2.57 -2.49
Net Debt to NOPAT		 1.17 0.29 0.30 0.53 0.50 9.37 26.49 -0.56 -1.15 -1.28 -1.45
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.39 -1.94 -2.15 -2.11
Altman Z-Score		 1.53 0.82 1.15 0.80 -1.03 1.87 3.62 1.57 2.26 2.29 3.85
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.21 1.98 2.25 2.12 2.29 2.38 3.05 1.95 2.19 2.16 2.28
Quick Ratio		 1.13 1.10 1.23 1.31 1.49 1.44 1.87 1.16 1.16 1.12 1.18
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.34 204 219 204 138 79 119 66 -2.68 -20 -32
Operating Cash Flow to CapEx		 -412.64% 126.11% -758.96% 0.00% -678.55% 293.70% -1,662.32% 0.00% 63.84% 300.44% -815.05%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 73.71 -3.64 -29.62 -83.99
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 17.71 1.86 10.96 -64.95
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.00 -1.05 7.31 -72.92
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.93 0.72 0.74 0.71 0.75 0.62 0.64 0.62 0.62 0.59 0.58
Accounts Receivable Turnover		 6.10 6.05 6.55 6.30 6.46 6.31 6.50 6.44 7.22 7.20 7.21
Inventory Turnover		 2.13 2.08 2.27 2.57 2.66 2.55 2.79 3.08 2.87 2.79 2.86
Fixed Asset Turnover		 8.14 7.59 7.53 7.59 7.85 7.45 7.50 7.58 7.51 7.37 7.35
Accounts Payable Turnover		 3.95 3.74 5.04 3.82 4.56 4.49 6.06 4.80 5.61 5.28 5.89
Days Sales Outstanding (DSO)		 59.87 60.36 55.69 57.91 56.53 57.85 56.15 56.64 50.55 50.67 50.63
Days Inventory Outstanding (DIO)		 171.01 175.33 160.95 141.80 137.44 143.24 130.93 118.39 127.00 130.68 127.62
Days Payable Outstanding (DPO)		 92.32 97.51 72.40 95.64 79.97 81.31 60.20 75.98 65.07 69.10 62.01
Cash Conversion Cycle (CCC)		 138.55 138.18 144.24 104.07 114.00 119.78 126.87 99.04 112.47 112.26 116.25
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 146 138 146 134 150 350 375 348 427 438 448
Invested Capital Turnover		 1.92 1.18 1.12 1.26 1.12 0.84 0.82 0.87 0.78 0.76 0.73
Increase / (Decrease) in Invested Capital		 -3.64 -212 -229 -214 -277 -88 -73 -81 -3.57 15 23
Enterprise Value (EV)		 336 232 250 181 150 209 266 391 514 536 897
Market Capitalization		 376 282 300 253 219 260 319 371 484 506 863
Book Value per Share		 $4.59 $4.60 $4.88 $5.13 $5.49 $10.07 $10.78 $9.64 $10.16 $10.43 $10.62
Tangible Book Value per Share		 $2.84 $2.80 $3.00 $3.20 $3.44 $3.47 $4.09 $2.75 $1.63 $1.67 $1.67
Total Capital		 191 192 201 210 228 411 433 443 457 468 473
Total Debt		 5.00 4.96 4.80 4.73 9.50 9.39 4.73 65 60 60 59
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 50 50 50 50
Net Debt		 -40 -49 -50 -71 -69 -52 -53 20 30 30 34
Capital Expenditures (CapEx)		 3.19 1.96 2.41 -2.68 1.85 1.79 1.56 -3.87 2.15 2.50 3.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 55 38 46 31 42 56 65 50 63 65 69
Debt-free Net Working Capital (DFNWC)		 99 92 101 107 121 117 123 94 93 95 94
Net Working Capital (NWC)		 94 87 96 102 111 107 118 80 83 85 85
Net Nonoperating Expense (NNE)		 -2.57 2.97 3.63 3.33 48 20 0.22 6.88 3.24 2.81 3.69
Net Nonoperating Obligations (NNO)		 -40 -49 -50 -71 -69 -52 -53 -30 30 30 34
Total Depreciation and Amortization (D&A)		 6.32 6.86 6.79 6.82 7.52 6.69 6.69 7.56 7.84 7.82 7.66
Debt-free, Cash-free Net Working Capital to Revenue		 19.25% 13.14% 15.61% 10.12% 12.99% 16.97% 19.40% 14.72% 18.74% 19.87% 21.61%
Debt-free Net Working Capital to Revenue		 35.05% 32.02% 34.40% 35.15% 37.20% 35.45% 36.54% 27.89% 27.73% 28.98% 29.26%
Net Working Capital to Revenue		 33.28% 30.28% 32.76% 33.59% 34.27% 32.60% 35.14% 23.53% 24.78% 26.00% 26.49%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.11) ($0.26) ($0.31) ($0.35) ($4.67) ($0.72) $1.15 ($0.55) ($0.24) ($0.21) ($0.33)
Adjusted Weighted Average Basic Shares Outstanding		 40.85M 40.92M 40.65M 40.18M 40.23M 40.22M 39.84M 39.48M 39.51M 39.49M 39.30M
Adjusted Diluted Earnings per Share		 ($0.11) ($0.26) ($0.31) ($0.35) ($4.67) ($0.72) $1.15 ($0.55) ($0.24) ($0.21) ($0.33)
Adjusted Weighted Average Diluted Shares Outstanding		 40.85M 40.92M 40.65M 40.18M 40.23M 40.22M 39.97M 39.48M 39.51M 39.49M 39.30M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 40.61M 40.47M 40.63M 40.28M 40.05M 39.86M 39.85M 39.67M 39.24M 39.13M 39.11M
Normalized Net Operating Profit after Tax (NOPAT)		 -4.68 -3.66 -6.15 -4.22 -8.20 -4.85 -6.72 -12 -3.89 -3.54 -5.40
Normalized NOPAT Margin		 -6.50% -5.02% -9.11% -5.95% -10.90% -6.14% -8.54% -13.23% -4.82% -4.14% -6.63%
Pre Tax Income Margin		 -6.12% -14.89% -18.77% -19.92% -265.68% -15.96% 44.31% -24.01% -11.97% -10.59% -16.99%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -23.27 -12.13 -12.23 -35.37
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -16.19 -8.49 -8.30 -24.44
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -18.98 -15.05 -15.88 -43.34
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -11.90 -11.41 -11.95 -32.41
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About AngioDynamics' Financials

When does AngioDynamics's fiscal year end?

According to the most recent income statement we have on file, AngioDynamics' financial year ends in May. Their financial year 2024 ended on May 31, 2024.

How has AngioDynamics' net income changed over the last 2 years?

AngioDynamics' net income appears to be on an upward trend, with a most recent value of -$184.35 million in 2024, rising from -$26.55 million in 2022. The previous period was -$52.44 million in 2023. See AngioDynamics' forecast for analyst expectations on what’s next for the company.

What is AngioDynamics's operating income?
AngioDynamics's total operating income in 2024 was -$192.44 million, based on the following breakdown:
  • Total Gross Profit: $154.70 million
  • Total Operating Expenses: $347.13 million
How has AngioDynamics revenue changed over the last 2 years?

Over the last 2 years, AngioDynamics' total revenue changed from $316.22 million in 2022 to $303.91 million in 2024, a change of -3.9%.

How much debt does AngioDynamics have?

AngioDynamics' total liabilities were at $112.09 million at the end of 2024, a 27.4% decrease from 2023, and a 12.6% decrease since 2022.

How much cash does AngioDynamics have?

In the past 2 years, AngioDynamics' cash and equivalents has ranged from $28.83 million in 2022 to $76.06 million in 2024, and is currently $76.06 million as of their latest financial filing in 2024.

How has AngioDynamics' book value per share changed over the last 2 years?

Over the last 2 years, AngioDynamics' book value per share changed from 10.95 in 2022 to 5.13 in 2024, a change of -53.1%.


Related Companies

This page (NASDAQ:ANGO) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Elon’s 2025 Silver Crisis (What It Means for You)
Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...
GoldenCrest Metals | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...
Crypto 101 Media | Sponsored
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
F1 Engineering Powers This Electric Marine Motor
The future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...
The Tomorrow Investor | Sponsored
Big Oil’s big pivot
The Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...
Stansberry Research | Sponsored
Trump Predicts Dollar Downfall
READ THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...
Augusta Precious Metals | Sponsored